BMC Medical Genomics (May 2009)

Data integration from two microarray platforms identifies bi-allelic genetic inactivation of <it>RIC8A </it>in a breast cancer cell line

  • Kleivi Kristine,
  • Wolf Maija,
  • Edgren Henrik,
  • Muggerud Aslaug,
  • Dejeux Emelyne,
  • Tost Jörg,
  • Sørlie Therese,
  • Kallioniemi Olli

DOI
https://doi.org/10.1186/1755-8794-2-26
Journal volume & issue
Vol. 2, no. 1
p. 26

Abstract

Read online

Abstract Background Using array comparative genomic hybridization (aCGH), a large number of deleted genomic regions have been identified in human cancers. However, subsequent efforts to identify target genes selected for inactivation in these regions have often been challenging. Methods We integrated here genome-wide copy number data with gene expression data and non-sense mediated mRNA decay rates in breast cancer cell lines to prioritize gene candidates that are likely to be tumour suppressor genes inactivated by bi-allelic genetic events. The candidates were sequenced to identify potential mutations. Results This integrated genomic approach led to the identification of RIC8A at 11p15 as a putative candidate target gene for the genomic deletion in the ZR-75-1 breast cancer cell line. We identified a truncating mutation in this cell line, leading to loss of expression and rapid decay of the transcript. We screened 127 breast cancers for RIC8A mutations, but did not find any pathogenic mutations. No promoter hypermethylation in these tumours was detected either. However, analysis of gene expression data from breast tumours identified a small group of aggressive tumours that displayed low levels of RIC8A transcripts. qRT-PCR analysis of 38 breast tumours showed a strong association between low RIC8A expression and the presence of TP53 mutations (P = 0.006). Conclusion We demonstrate a data integration strategy leading to the identification of RIC8A as a gene undergoing a classical double-hit genetic inactivation in a breast cancer cell line, as well as in vivo evidence of loss of RIC8A expression in a subgroup of aggressive TP53 mutant breast cancers.